在开发这种所谓癌症免疫疗法的公司中,默克集团(Merck & Co)、百时美施贵宝(Bristol-Myers Squibb)、罗氏(Roche)及阿斯利康(AstraZeneca)赫然在列。这种免疫疗法的原理,是利用机体的免疫力对抗癌细胞。
The earliest of these have been launched in the US in recent months at prices amounting to about $150,000 a year — generating fresh optimism around the pharmaceuticals industry after a decade of sluggish growth.
这种治疗方法最早于最近几个月在美国推出,其价格总计为一年约15万美元。对于经历了十年增长乏力的制药业来说,这一天价方案催生了新的乐观情绪。
However, the expected surge of expensive new cancer drugs has raised questions over their affordability for healthcare systems already struggling with the rising cost of caring for an ageing world population.
然而,昂贵的癌症新药如期涌现,也引发了大量质疑:面对全球人口老龄化而导致的成本上升,已经不堪重负的医疗系统还能否负担起这些新药。
“Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer,” said the IMS report.
艾美仕报告表示:“诊断时间提前、治疗时期延长、以及药物治疗有效性增加,都在助推癌症药物开支的增加。”
【全球癌症药品年度开支创纪录】相关文章:
★ 用餐时交出手机就能获赠免费披萨 这家店已送出50张大披萨!
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15